内镜下锯齿状息肉切除后异时性结直肠癌或进展期病变的危险因素:系统综述与Meta分析
该系统综述与Meta分析纳入14项研究共493,949例患者,评估基线锯齿状息肉(SP)的大小、异型增生、位置和多发性与异时性结直肠癌(CRC)或进展期息肉风险的关系。结果显示基线进展期SP、≥10 mm SP及伴异型增生SP的异时性CRC风险显著升高,风险幅度与进展期腺瘤相似,支持对进展期SP患者进行3年监测的现行推荐。
要点
- 基线进展期SP患者异时性CRC风险高于非进展期SP(RR 1.84)和正常结肠镜者(RR 2.92)。
- ≥10 mm SP患者异时性CRC风险高于<10 mm者(RR 2.61)和正常结肠镜者(RR 3.52)。
- 伴异型增生SP患者异时性CRC风险高于正常结肠镜者(RR 2.71);近端SP或≥3个SP未显示风险增加。
核心结论
- 随访4.9年后,基线进展期SP患者的CRC风险显著升高,风险幅度与进展期腺瘤相似,支持对进展期SP患者进行3年监测的现行推荐。
研究设计与样本
- 系统检索PubMed、Embase和Cochrane从建库至2023年12月31日的队列研究、病例对照研究和临床试验,纳入14项研究共493,949例患者(平均年龄59.5岁,55%为男性,平均随访4.9年)。
- 按基线SP大小、异型增生、位置和多发性分层评估监测期间CRC或进展期息肉(进展期腺瘤或进展期SP)发生率,进展期SP定义为≥10 mm或伴异型增生。
- 采用随机效应模型计算合并相对风险(RR)进行Meta分析。
主要发现
- 每1000人年CRC发生率:进展期SP为2.09(95%CI 1.29-2.90),≥10 mm SP为1.52(95%CI 0.78-2.25),伴异型增生SP为5.86(95%CI 2.16-9.56),近端SP为1.18(95%CI 0.77-1.60),≥3个SP为0.52(95%CI 0.08-1.12),非进展期SP为0.50(95%CI 0.35-0.66),正常结肠镜为0.44(95%CI 0.41-0.46)。
- 异时性CRC风险:进展期SP vs 非进展期SP的RR为1.84(95%CI 1.11-3.04),进展期SP vs 正常结肠镜的RR为2.92(95%CI 2.26-3.77)。
- 异时性CRC风险:≥10 mm SP vs <10 mm SP的RR为2.61(95%CI 1.43-4.77),≥10 mm SP vs 正常结肠镜的RR为3.52(95%CI 2.17-5.69),伴异型增生SP vs 正常结肠镜的RR为2.71(95%CI 2.00-3.67)。
- 近端SP vs 远端SP、≥3个SP vs 1或2个SP未发现CRC或进展期息肉风险增加。
关键数值与推荐
- 进展期SP定义为≥10 mm或伴异型增生。
- 基线进展期SP患者异时性CRC风险高于非进展期SP(RR 1.84;95%CI 1.11-3.04)和正常结肠镜(RR 2.92;95%CI 2.26-3.77)。
- 基线≥10 mm SP患者异时性CRC风险高于<10 mm SP(RR 2.61;95%CI 1.43-4.77)和正常结肠镜(RR 3.52;95%CI 2.17-5.69)。
- 基线伴异型增生SP患者异时性CRC风险高于正常结肠镜(RR 2.71;95%CI 2.00-3.67)。
- 近端SP vs 远端SP、≥3个SP vs 1或2个SP未发现CRC或进展期息肉风险增加。
临床怎么用
- 研究结果支持对基线进展期SP患者进行3年监测的现行推荐。
- 基线进展期SP、≥10 mm SP或伴异型增生SP的患者异时性CRC风险升高,风险幅度与进展期腺瘤相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Serrated polyps (SPs) are precursors to 15% to 20% of colorectal cancers (CRCs). However, there are uncertainties regarding which SPs require surveillance and at what intervals, with recommendations adapted from those for adenomas in the absence of solid evidence. Our aim was to assess which SP risk characteristics relate to a higher risk of metachronous CRC or advanced polyps. METHODS: We systematically searched PubMed, Embase, and Cochrane for cohort studies, case-control studies, and clinical trials from inception to December 31, 2023, of CRC or advanced polyps (advanced adenoma [AA] or advanced SP) incidence at surveillance stratified by baseline SP size, dysplasia, location, and multiplicity. We defined advanced SPs as those ≥10 mm or with dysplasia. CRC and advanced polyp incidence per 1000 person-years were estimated. We performed a meta-analysis by calculating pooled relative risks (RRs) using a random-effects model. RESULTS: A total of 5903 studies were reviewed, and 14 were included with 493,949 patients (mean age, 59.5 years; 55% men). The mean follow-up was 4.9 years. CRC incidence per 1000 person-years was 2.09 (95% confidence interval [CI], 1.29-2.90) for advanced SPs, 1.52 (95% CI, 0.78-2.25) for SPs of ≥10 mm, 5.86 (95% CI, 2.16-9.56) for SPs with dysplasia, 1.18 (95% CI, 0.77-1.60) for proximal SPs, 0.52 (95% CI, 0.08-1.12) for ≥3 SPs, 0.50 (95% CI, 0.35-0.66) for nonadvanced SPs, and 0.44 (95% CI, 0.41-0.46) for normal colonoscopy findings. Metachronous CRC risk was higher in advanced SPs versus nonadvanced SPs (RR, 1.84; 95% CI, 1.11-3.04) and versus normal colonoscopy findings (RR, 2.92; 95% CI, 2.26-3.77), in SPs of ≥10 mm versus <10 mm (RR, 2.61; 95% CI, 1.43-4.77) and versus normal colonoscopy findings (RR: 3.52; 95% CI, 2.17-5.69); and in SPs with dysplasia versus normal colonoscopy findings (RR: 2.71; 95% CI, 2.00-3.67). No increase in CRC or advanced polyp risk was found in patients with proximal versus distal SPs, nor in ≥3 SPs versus 1 or 2 SPs. CONCLUSIONS: CRC risk is significantly higher in patients with baseline advanced SPs after 4.9 years of follow-up, with risk magnitudes similar to those described for AA, supporting the current recommendation for 3-year surveillance in patients with advanced SPs.
引用
- Baile-Maxía S, Mangas-Sanjuán C, Ladabaum U, et al. Risk factors for metachronous colorectal cancer or advanced lesions after endoscopic resection of serrated polyps: a systematic review and meta-analysis. Gastrointest Endosc. 2024. PMID: 38851458. doi:10.1016/j.gie.2024.05.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。